PI3K/AKT/mTOR signaling in cancer -- 专题文献

近5年高被引文献

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer

review Full Text OpenAlex 1697 FWCI265.4519

**Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS ^G12C Mutation**

article Full Text OpenAlex 901 FWCI73.6456

Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease

review Full Text OpenAlex 751 FWCI117.6488

PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?

review Full Text OpenAlex 731 FWCI62.1954

Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer

article Full Text OpenAlex 615 FWCI161.8292

Pan-KRAS inhibitor disables oncogenic signalling and tumour growth

article Full Text OpenAlex 454 FWCI71.2455

mTOR substrate phosphorylation in growth control

review Full Text OpenAlex 405 FWCI33.3449

Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update

review Full Text OpenAlex 322 FWCI143.2565

Multiple myeloma: 2024 update on diagnosis, risk‐stratification, and management

review Full Text OpenAlex 319 FWCI148.4498

EGFR signaling pathway as therapeutic target in human cancers

review Full Text OpenAlex 304 FWCI42.7204

专题：PI3K/AKT/mTOR signaling in cancer

最新文献

**Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C–Mutated Tumors**

Abstract RF7-04: Gedatolisib, a multi-target PI3K/AKT/mTOR (PAM) inhibitor, plus fulvestrant with or without palbociclib for second-line (2L) treatment of patients with HR+/HER2-/PIK3CA-wild type (WT) advanced breast cancer (ABC): updated results from the randomized, phase 3 VIKTORIA-1 trial

(E)-N'-(4-chlorobenzylidene)-5-methyl-1H-pyrazole-3-carbohydrazide as a potential PI3Kα targeting scaffold, synthesis, X-ray crystallography, DFT, molecular docking, molecular dynamics simulations, and MMGBSA analysis

Case Report: mTOR inhibitor treatment for epithelioid angiomyolipoma harboring biallelic TSC2 mutations

Novel hydrazone-derived pyrazole-benzofuran compounds inhibit cancer cell growth by targeting MMPs, caspases, and PI3K/AKT/mTOR signaling pathway

Properties of FDA-approved small molecule protein kinase inhibitors: A 2026 update

Synthesis, Molecular Docking and ADMET Analysis of New Asymmetric 2,4‐Disubstituted Thiazole Amino Acids by Microwave Techniques to Explore Potential Drugs for Breast Cancer

Oncogenic PI3Kα variants reveal graded conformational spectrum with mutation-specific cryptic pockets

An integrated, scaled approach to resolve TSC2 variants of uncertain significance

Loss of the translational repressor 4E-BP1 promotes skin carcinogenesis

近5年高被引文献

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer

**Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS ^G12C Mutation**

Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease

PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?

Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer

Pan-KRAS inhibitor disables oncogenic signalling and tumour growth

mTOR substrate phosphorylation in growth control

Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update

Multiple myeloma: 2024 update on diagnosis, risk‐stratification, and management

EGFR signaling pathway as therapeutic target in human cancers

专题：PI3K/AKT/mTOR signaling in cancer

最新文献

Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C–Mutated Tumors

Abstract RF7-04: Gedatolisib, a multi-target PI3K/AKT/mTOR (PAM) inhibitor, plus fulvestrant with or without palbociclib for second-line (2L) treatment of patients with HR+/HER2-/PIK3CA-wild type (WT) advanced breast cancer (ABC): updated results from the randomized, phase 3 VIKTORIA-1 trial

(E)-N'-(4-chlorobenzylidene)-5-methyl-1H-pyrazole-3-carbohydrazide as a potential PI3Kα targeting scaffold, synthesis, X-ray crystallography, DFT, molecular docking, molecular dynamics simulations, and MMGBSA analysis

Case Report: mTOR inhibitor treatment for epithelioid angiomyolipoma harboring biallelic TSC2 mutations

Novel hydrazone-derived pyrazole-benzofuran compounds inhibit cancer cell growth by targeting MMPs, caspases, and PI3K/AKT/mTOR signaling pathway

Properties of FDA-approved small molecule protein kinase inhibitors: A 2026 update

Synthesis, Molecular Docking and ADMET Analysis of New Asymmetric 2,4‐Disubstituted Thiazole Amino Acids by Microwave Techniques to Explore Potential Drugs for Breast Cancer

Oncogenic PI3Kα variants reveal graded conformational spectrum with mutation-specific cryptic pockets

An integrated, scaled approach to resolve TSC2 variants of uncertain significance

Loss of the translational repressor 4E-BP1 promotes skin carcinogenesis

近5年高被引文献

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer

Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation

Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease

PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?

Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer

Pan-KRAS inhibitor disables oncogenic signalling and tumour growth

mTOR substrate phosphorylation in growth control

Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update

Multiple myeloma: 2024 update on diagnosis, risk‐stratification, and management

EGFR signaling pathway as therapeutic target in human cancers

**Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C–Mutated Tumors**

**Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS ^G12C Mutation**